Changing paradigm in the treatment of amyloidosis: From disease-modifying drugs to anti-fibril therapy

Cardiac amyloidosis is a rare, debilitating, and usually fatal disease increasingly recognized in clinical practice despite patients presenting with non-specific symptoms of cardiomyopathy. The current standard of care (SoC) focuses on preventing further amyloid formation and deposition, either with...

Descripción completa

Detalles Bibliográficos
Autores principales: Quarta, C. Cristina, Fontana, Marianna, Damy, Thibaud, Catini, Julia, Simoneau, Damien, Mercuri, Michele, Garcia-Pavia, Pablo, Maurer, Mathew S., Palladini, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808970/
https://www.ncbi.nlm.nih.gov/pubmed/36606280
http://dx.doi.org/10.3389/fcvm.2022.1073503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808970/
https://www.ncbi.nlm.nih.gov/pubmed/36606280
http://dx.doi.org/10.3389/fcvm.2022.1073503

Ejemplares similares